InteRNA Genomics

InteRNA Technologies is a clinical-stage Dutch biotechnology company specializing in the development of microRNA (miRNA)-based therapeutics for cancer. The company's lead candidate, INT-1B3, is a chemically modified mimic of the tumor suppressor miR-193a-3p, delivered via a proprietary lipid nanoparticle (LNP) formulation. This therapeutic approach is designed to simultaneously address multiple hallmarks of cancer by targeting oncogenic signaling pathways and modulating the immunosuppressive tumor microenvironment. Founded as a spin-off from the Hubrecht Institute, InteRNA utilizes a high-throughput functional screening platform to identify and validate miRNAs with potent anti-tumor activity.